Targeted Cyclodextrins

Salmaso, Stefano; Sonvico, Fabio

doi:10.1002/9780470926819.ch13

Cited by 1 publication

(1 citation statement)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cyclodextrins (CD), cyclic oligosaccharides constituted by seven d -glucose units linked by α-1,4 glucosidic bonds, and their conjugates have been widely used to complex and deliver different kind of pharmaceutics, , including anticancer drugs. , Despite of a few studies demonstrate the utilize of CD as pharmaceutical excipients in formulation with Sor, only rare reports show the ability of natural or commercial CD to form complexes with anticancer drugs . Over the past two decades, scientists developed a plethora of amphiphilic CD (aCD) able to increase bioavailability and modulate pharmacokinetics of chemotherapeutics .…”

Section: Introductionmentioning

confidence: 99%

Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells

et al. 2015

View full text Add to dashboard Cite

Sorafenib (Sor), an effective chemiotherapeutic drug utilized against hepatocellular carcinoma (HCC), robustly interacts with nonionic amphiphilic cyclodextrin (aCD, SC6OH), forming, in aqueous solution, supramolecular complexes that behave as building blocks of highly water-dispersible colloidal nanoassemblies. SC6OH/Sor complex has been characterized by complementary spectroscopic techniques, such as UV-vis, steady-state fluorescence and anisotropy, resonance light scattering and (1)H NMR. The spectroscopic evidences and experiments carried out in the presence of an adamantane derivative, which competes with drug for CD cavity, agree with the entrapment of Sor in aCD, pointing out the role of the aCD cavity in the interaction between drug and amphiphile. Nanoassemblies based on SC6OH/Sor display size of ∼200 nm, negative zeta-potential (ζ = -11 mV), and both maximum loading capacity (LC ∼ 17%) and entrapment efficiency (EE ∼ 100%). Kinetic release profiles show a slower release of Sor from nanoassemblies with respect to the free drug. SC6OH/Sor nanoassemblies have very low hemolytic activity and high efficiency in vitro in decreasing cell growth and viability of HCC cell lines, such as HepG2, Hep3B, and PLC/PRF/5, opening promising chances to their in vivo applications.

show abstract